If you or a loved one has taken Reglan for an extended period, you may be concerned about the risk of tardive dyskinesia. This movement disorder, characterized by involuntary repetitive movements, has been a subject of ongoing clinical research. Building on decades of pharmacovigilance, this page provides an updated overview of the evidence linking Reglan to tardive dyskinesia, including symptom recognition and risk management.
Reglan (metoclopramide) is a medication approved for short-term use in adults with symptomatic gastroesophageal reflux or diabetic gastroparesis. However, its use carries a significant risk of tardive dyskinesia (TD), a potentially irreversible movement disorder. This section examines the clinical presentation of TD, the pharmacology of Reglan, the mechanistic link between the drug and the condition, and the legal considerations for affected patients in Arizona, particularly regarding the statute of limitations. Tardive dyskinesia is characterized by involuntary, repetitive movements, often involving the face, tongue, and extremities. According to the FDA-approved labeling, TD is "a syndrome of potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Diagnosis is clinical, based on observation of these movements after exposure to a dopamine-blocking agent like metoclopramide. The condition can be masked by continued use of the drug, as metoclopramide "may suppress, or partially suppress, the signs of TD, and may delay the diagnosis of TD because it may mask the underlying disease process" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Reglan is a dopamine receptor antagonist that increases gastrointestinal motility. Its pharmacology is directly linked to TD through chronic dopamine blockade in the basal ganglia, leading to supersensitivity of dopamine receptors and subsequent involuntary movements. The risk of developing TD increases with longer treatment duration and higher cumulative doses. The boxed warning states: "Metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder. In patients treated with metoclopramide, including Reglan, the risk of developing TD increases with duration of treatment and total cumulative dosage" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling emphasizes using Reglan for the shortest duration necessary and reassessing the need for continued treatment. For gastroesophageal reflux, the maximum approved treatment duration is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For diabetic gastroparesis, the labeling advises avoiding treatment longer than 12 weeks, but if longer use is unavoidable, routine monitoring for TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, many patients have been prescribed Reglan for extended periods, increasing their risk. The mechanistic pathway involves metoclopramide's blockade of dopamine D2 receptors in the striatum. Chronic blockade leads to upregulation of these receptors, resulting in an imbalance in the direct and indirect pathways of motor control. This produces the hyperkinetic movements seen in TD. The FDA labeling notes that Reglan is contraindicated in patients with a history of TD and should be immediately discontinued if signs or symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, the latency between exposure and symptom onset can vary, sometimes appearing months or years after starting the drug, and may even occur after discontinuation.
For affected patients in Arizona, legal considerations center on the adequacy of warnings and the statute of limitations. The FDA labeling includes a boxed warning about TD, but questions may arise about whether prescribers and patients were adequately informed of the risks, especially for off-label or long-term use. The labeling states: "Use Reglan for the shortest duration of treatment and periodically reassess the need for continued treatment" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If a patient was not warned about the risk of TD or was prescribed Reglan for longer than recommended, this could form the basis of a claim. The statute of limitations for personal injury claims in Arizona is generally two years from the date the injury is discovered or should have been discovered. For TD, this can be complex because symptoms may develop gradually and may be initially misattributed. The timeline between exposure and documented harm is critical. The FDA labeling indicates that TD can be "potentially irreversible" and may be masked by continued drug use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Therefore, the discovery date may be when a patient is diagnosed with TD after stopping Reglan or when symptoms become noticeable. Patients should consult an attorney to determine the applicable deadline based on their specific circumstances. Attorney-related considerations include the need to document the duration of Reglan use, cumulative dosage, and any monitoring or lack thereof. The labeling advises that for patients with diabetic gastroparesis, if longer-term use is unavoidable, routine monitoring for TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Failure to monitor could be evidence of negligence. Additionally, the labeling warns against concomitant use with other drugs known to cause TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If a patient was prescribed multiple such drugs, this may strengthen a claim. In summary, Reglan use is associated with a well-documented risk of TD, which increases with longer treatment duration. The FDA labeling provides clear warnings and usage limits, but many patients have been exposed beyond these limits. For Arizona residents, the statute of limitations requires prompt action after diagnosis. Affected individuals should seek legal advice to evaluate their case and ensure timely filing.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Arizona, the statute of limitations for personal injury claims is generally two years from the date the injury is discovered or should have been discovered. For tardive dyskinesia caused by Reglan, this can be complex because symptoms may develop gradually. The discovery date is often when a patient is diagnosed with TD after stopping Reglan or when symptoms become noticeable. It is crucial to consult an attorney promptly to determine the applicable deadline based on individual circumstances.
Reglan (metoclopramide) is a dopamine receptor antagonist. Chronic use leads to dopamine blockade in the basal ganglia, causing upregulation of dopamine receptors and supersensitivity. This results in an imbalance in motor control pathways, producing the involuntary movements characteristic of tardive dyskinesia. The risk increases with longer treatment duration and higher cumulative doses, as highlighted in the FDA boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.